CHMP review bolsters Pradaxa's safety profile but strengthens label
This article was originally published in Scrip
Executive Summary
The EMA is to update the product information of Boehringer Ingelheim's direct thrombin inhibitor Pradaxa (dabigatran etexilate) to give clearer guidance to doctors and patients on how to reduce and manage the risk of bleeding associated with the anticoagulant.